Form 4: Hims & Hers CEO Andrew Dudum Reports RSU Vesting

Hims & Hers Health, Inc. CEO Andrew Dudum reported the vesting of Restricted Stock Units and related tax withholding transactions on December 15, 2025.

Summary

• Andrew Dudum, CEO, Director, and 10% Owner of Hims & Hers Health, Inc. (HIMS), reported transactions on December 15, 2025.
• Acquired 164,369 shares of Class A Common Stock through the vesting and settlement of Restricted Stock Units (RSUs).
• Disposed of 90,660 shares of Class A Common Stock at a price of $36.25 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Andrew Dudum directly beneficially owns 878,732 shares of Class A Common Stock.
• Indirect beneficial ownership includes 384,731 shares via Andrew Dudum 2015 Trust, 508,030 shares via AD 2022 GRAT, 186,723 shares via AD 2025 GRAT, 47,524 shares via Dudum Family Community Property Trust, 791,117 shares via AD 2022 GRAT 2, 1,080,972 shares via Dudum Legacy 2021 Trust, 2,214,769 shares via Dudum Family Heritage Trust, and 3,004,071 shares via Dudum Family 2021 Trust.
• Derivative securities transactions involved the conversion of 35,242, 35,446, 74,530, and 19,151 Restricted Stock Units into Class A Common Stock, with a conversion price of $0.
• The RSUs are subject to a 4-year service-based vesting requirement, with installments on Company Quarterly Vesting Dates (March 15, June 15, September 15, December 15).

Sentiment

Score: 5

Explanation: The filing reports routine executive compensation transactions (RSU vesting and tax withholding) which are neutral in sentiment. There are no unexpected positive or negative financial outcomes or strategic shifts indicated.

Positives

• The vesting of Restricted Stock Units indicates continued long-term commitment and retention of the CEO.
• The acquisition of shares through RSU vesting increases the CEO's direct equity stake in the company.

Negatives

• The disposition of 90,660 shares to cover tax obligations represents a reduction in the CEO's direct shareholding, though this is a standard practice for RSU vesting.

Future Outlook

The filing indicates ongoing service-based vesting requirements for Restricted Stock Units over a 4-year period, with future vesting dates occurring quarterly on March 15, June 15, September 15, and December 15.

Industry Context

This filing is a routine disclosure of executive compensation in the form of equity, common across publicly traded companies, particularly in the healthcare technology sector where Hims & Hers operates. It reflects standard practices for RSU vesting and associated tax obligations.

Related Party Transactions

• The transactions involve the CEO, Andrew Dudum, and the issuer, Hims & Hers Health, Inc., which are considered related parties.
• Indirect beneficial ownership is held through various trusts associated with Andrew Dudum.

Stakeholder Impact

• Shareholders: The disposition of shares for tax purposes slightly increases the public float, but the overall impact on share price is typically minimal for routine insider transactions. The CEO's continued equity ownership aligns his interests with shareholders.
• Employees: The RSU vesting structure is a common form of equity compensation, potentially signaling a standard approach to executive incentives.

Next Steps

• Future vesting of remaining Restricted Stock Units will occur in substantially equal quarterly installments on March 15, June 15, September 15, and December 15, as per the 4-year service-based vesting schedule.

Key Dates

Keywords

Hims & Hers Health, HIMS, Andrew Dudum, SEC Form 4, Restricted Stock Units, RSU vesting, insider transaction, stock ownership, executive compensation, tax withholding